Bausch + Lomb price target raised to $21 from $19 at Citi

Citi raised the firm's price target on Bausch + Lomb to $21 from $19 and keeps a Buy rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks that may be positioned for a catch-up trade, the analyst tells investors in a preview.